Repaglinide troche and preparation method thereof

A tablet and formula technology, applied in the field of pharmaceutical preparations, can solve the problems of complicated operation steps, increased labor cost, uneven particle size distribution, etc.

Active Publication Date: 2014-03-05
华益泰康药业股份有限公司
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite satisfactory dissolution, this wet granulation method has many disadvantages
For example, the operation steps in production are complicated, including binder solution preparation, soft material preparation, granule sizing, granule drying, mixture mixing and blending powder tableting; more equipment is required in production, including liquid preparation device, wet granulation Machines, granulators, ovens, mixers and tablet presses increase labor costs and prolong operating time; the drying temperature of wet granules is not easy to control, and the uneven particle size distribution can easily cause content differences between granules, content decline and related substances ( For example, the problem of increased impurities; after wet granulation, the tablet disintegrates into granulated particles, which are not primary particles, which is not conducive to the dissolution of active drugs; in addition, it is important that the wet granulation step introduces A large amount of water, and the introduction of water will cause the active substance to decompose or undergo crystal transformation during the manufacturing or storage process, thus affecting the stability of the drug
[0009] The conceivable preparation methods used to solve the above problems may be dry granulation tableting method and powder direct tableting method, however, limited by the particularity of repaglinide's own physical and chemical properties and the requirements of oral small dose preparations, since Since its listing 15 years ago, there have been no successful dry granulation tableting and powder direct tableting products, and there are no literature reports in this regard

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Repaglinide troche and preparation method thereof
  • Repaglinide troche and preparation method thereof
  • Repaglinide troche and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Example 1 Preparation of Repaglinide Tablets by Powder Direct Compression

[0102] Adopt commercially available repaglinide crude drug, pulverize with a jet mill, and detect the particle size after pulverization; repeat pulverization as required until the particle size is D 90 =8μm. The tablet prescription is shown in Table 1:

[0103] Table 1: Prescription for 1000 repaglinide tablets (2mg / tablet)

[0104] #

Material

1000 prescription quantity (g)

Percentage (%)

1

Repaglinide (8μm)

2

2

2

Calcium hydrogen phosphate

40

40

3

meglumine

0.15

0.15

4

Poloxamer 188

2

2

5

Microcrystalline Cellulose PH102

54.15

54.15

6

Crospovidone

1

1

7

Magnesium stearate

0.5

0.5

8

red iron oxide

0.2

0.2

[0105] Described tablet adopts direct compression method to prepare, and concrete steps are:

[0106] A. P...

Embodiment 2

[0113] Example 2 Preparation of Repaglinide Tablets by Powder Direct Compression

[0114] Using the same prescription and process method in Example 1 to prepare 2mg / tablets, the difference is that the particle size D of repaglinide 90 is 15 μm.

Embodiment 3

[0115] Example 3 Preparation of Repaglinide Tablets by Powder Direct Compression

[0116] Using the same prescription and process method in Example 1 to prepare 2mg / tablets, the difference is that the particle size D of repaglinide 90 is 28 μm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to an oral troche which contains repaglinide or pharmaceutically acceptable derivatives of repaglinide as well as a preparation method of the oral troche. According to the preparation method, powder of repaglinide or pharmaceutically acceptable derivatives of repaglinide is directly pressed into troche, so that the production cost is remarkably lowered, and the disintegration and the dissolution rate are greatly improved. The bioavailability and the stability of the medicine can be improved, and the problem of low content uniformity of existing small-dose medicines formed by the direct pressing method is overcome, so that the quality of the troche is better guaranteed.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to an oral tablet containing repaglinide or a pharmaceutically acceptable derivative thereof, and a method for preparing the oral tablet. Background technique [0002] Whether it is a developed country or a developing country, diabetes, especially type II diabetes, has developed into an epidemic in modern society and a worldwide public health problem that seriously threatens human health. [0003] Repaglinide is a first-line oral hypoglycemic drug developed by Germany's Novo Nordisk for the treatment of type 2 diabetes. It was first launched in the United States in 1997. Its trade name is: Later, it was listed in Europe and my country successively. The trade name is: It is a methylbenzylamine benzoic acid (CBMA) derivative with the following structural formula: [0004] [0005] The drug binds to a specific site on the β-cell membrane, closes the ATP-depen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/451A61K9/20A61P3/10
Inventor 徐国杰谭海松诸弘刚高春荣赵烈杨霖洪江生贾强
Owner 华益泰康药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products